Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Dr Joel Neal - Stanford University, Stanford, USA
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )
18 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSC...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spai...
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Jun 2019
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Expanding clinical trial eligibility criteria: Risks and solutions
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )
6 Jun 2019
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients wit...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )
6 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of patien...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage ...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, US...
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as tr...
Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we ...
Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall survival...
Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019